imetelstat: Clinical Trials

11 trials of imetelstat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 1 active not recruiting, 1 not yet recruiting, 1 terminated. 11 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 211Completed 7, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Withdrawn 1
Phase 31Active not recruiting 1

Follow imetelstat: new trials by email Literature Review of imetelstat trials Research Report on imetelstat

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms
Imetelstat - Phase II, Imetelstat
Phase 2Not yet recruitingM.D. Anderson Cancer Center302027-04-082026-11-12
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
Imetelstat sodium - Myelodysplastic Syndromes, Acute Myeloid Leukemia
Phase 2CompletedGCP-Service International West GmbH462023-06-052026-10-02
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Imetelstat Sodium, Placebo - Myelodysplastic Syndromes
Phase 2 / Phase 3Active not recruitingGeron Corporation2892016-01-122026-07-17
Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg - Myelofibrosis
Phase 2CompletedGeron Corporation1072015-08-282021-09-14
Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Imetelstat Sodium, Laboratory Biomarker Analysis - Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma
Phase 2WithdrawnChildren's Oncology Group2014-06-302018-08-07
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
imetelstat sodium - Anaplastic Astrocytoma, Anaplastic Ependymoma
Phase 2TerminatedPediatric Brain Tumor Consortium432013-03-012018-07-20
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
Imetelstat - Primary Myelofibrosis, Secondary Myelofibrosis
Phase 2CompletedGeron Corporation802012-10-292021-09-21
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
Imetelstat - Essential Thrombocythemia, Polycythemia Vera
Phase 2CompletedGeron Corporation202010-12-012016-01-26
Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
Imetelstat (7.5 mg/kg), lenalidomide standard of care, Imetelstat (9.4 mg/kg) - Multiple Myeloma
Phase 2CompletedGeron Corporation132010-11-012026-06-17
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
Imetelstat sodium, Bevacizumab, Paclitaxel - Locally Recurrent or Metastatic Breast Cancer
Phase 2CompletedGeron Corporation1662010-11-012016-01-26
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
imetelstat, Bevacizumab - Non-small Cell Lung Cancer
Phase 2CompletedGeron Corporation1162010-05-012016-01-26

Conditions studied

Myelodysplastic Syndromes (3)  ·  Primary Myelofibrosis (2)  ·  Recurrence (2)  ·  Astrocytoma (1)  ·  Brain Stem Neoplasms (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Disease (1)  ·  Ependymoma (1)  ·  Glioblastoma (1)  ·  Gliosarcoma (1)  ·  Hepatoblastoma (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Multiple Myeloma (1)  ·  Myeloproliferative Disorders (1)

Sponsors

Geron Corporation (7)  ·  Children's Oncology Group (1)  ·  GCP-Service International West GmbH (1)  ·  M.D. Anderson Cancer Center (1)  ·  Pediatric Brain Tumor Consortium (1)

Countries

United States (9)  ·  Germany (5)  ·  Canada (4)  ·  France (3)  ·  Belgium (2)  ·  Israel (2)  ·  Italy (2)  ·  South Korea (2)  ·  Spain (2)  ·  Switzerland (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Czechia (1)  ·  Netherlands (1)  ·  Poland (1)

Top investigators

Bravo G Montalban, MD (1)  ·  Carol Ann Huff, M.D. (1)  ·  Joan Schiller, MD (1)  ·  Joe Eid (1)  ·  Kathy Miller, MD (1)  ·  Maryam Fouladi (1)  ·  Patrick Thompson (1)  ·  Ted Shih, PharmD (1)  ·  Tymara Berry, MD (1)  ·  Uwe Platzbecker, MD (1)

Results publications

PMID 26332545, PMID 26332546, PMID 32732354, PMID 33108243, PMID 34138638, PMID 38048786, PMID 41135032, PMID 41568521

NIH funding

2015 (2), U01CA081457 (1), U10CA098543 (1)